WO2006106220A2 - Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage - Google Patents
Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage Download PDFInfo
- Publication number
- WO2006106220A2 WO2006106220A2 PCT/FR2006/000730 FR2006000730W WO2006106220A2 WO 2006106220 A2 WO2006106220 A2 WO 2006106220A2 FR 2006000730 W FR2006000730 W FR 2006000730W WO 2006106220 A2 WO2006106220 A2 WO 2006106220A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mono
- oligosaccharides
- oligosaccharide
- vectors
- adhesion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to compositions for topical application, said compositions being able to limit the adhesion of microorganisms on the skin of warm-blooded animals with peeling. It also relates to uses of such compositions in the veterinary field.
- the skin of animals is constantly attacked by pathogenic micro-organisms.
- the horny layer of the epidermis by its pH, its relatively low water content and the presence of antibiotic peptides having a bactericidal action, acts as the first barrier against these pathogenic microorganisms.
- Antibiotics can effectively fight against these pathogenic microorganisms, thanks to their bacteriostatic and / or bactericidal actions.
- the surface of certain bacteria is known to contain lectins, which enable them to recognize and bind to specific sugar radicals specific to glycoproteins and glycolipids located on the surface of epithelial cells. It has been demonstrated, in vitro, that by mimicking the sweet radicals of the glycoproteins and glycolipids of epithelial cells, certain saccharides limit the adhesion of bacteria such as Pseudomonas aeruginosa to glycoproteins such as fibronectins ("Inhibition of Pseudomonas aeruginosa adhesion to fibronectin by PA-IL and monosaccharides: "Involvement of a lectin-like process", Julie Rebiere-Huet, Patrick Di Martino, and Christian Hulen, Can J.
- the solution of the invention to this problem has as its first object a composition for topical application, characterized in that it comprises at least a first and a second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being capable of limiting the adhesion of microorganisms to the skin of warm-blooded animals with peeling.
- the pathogenic microorganisms in particular considered are Staphylococcus intermedius, Pseudomonas aeruginosa and Malassezia. pachydermatis.
- warm-blooded animals and pets are pets and especially dogs, cats or horses.
- Its second object is the use of a first and a second mono- or oligosaccharide, each of said first and second mono- or oligosaccharides being able to limit the adhesion of microorganisms, for the preparation of a composition topical for prevention, for the control or treatment of cutaneous disorders of warm-blooded animals.
- composition comprising charged micro- or nanoparticulate vectors, unloaded micro- or nanoparticulate vectors, said vectors comprising at least one active agent such as a mono- or oligosaccharide.
- a composition comprises at least two mono- or oligosaccharides each of said mono- or oligosaccharides being able to limit the adhesion of microorganisms, the inhibition of microorganisms affects a much larger number families and one Effective inhibition of microorganisms is observed so that the adhesion of pathogenic microorganisms to the skin of warm-blooded animals is greatly diminished.
- the addition of a third mono- or oligosaccharide is still very advantageous. Nevertheless, the addition of many other mono- or oligosaccharides would show little use.
- composition according to the invention comprises at least a first and a second mono- or oligosaccharide, said first mono- or oligosaccharide being different from said second mono- and / or oligosaccharide.
- Monosaccharides are molecules made up of three chemical elements: carbon, hydrogen and oxygen. They contain from 3 to 8 carbon atoms.
- pentoses such as arabinose, ribose, ribulose, xylose, xylulose and lyxose
- hexoses such as allose, altrose, fructose, galactose, glucose, gulose, idose, mannose, rhamnose, sorbose, talose and tagatose.
- the oligosaccharides are homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides. In practice, it is di-, tri- or tetramers of monosaccharides.
- the first and second mono- or oligosaccharides are each capable of preventing and / or limiting the adhesion of microorganisms on the skin of warm-blooded animals, in particular on keratinocytes of the skin of these animals and, more particularly, to the corneocytes of the skin of these animals.
- they mimic the sweet radicals of glycoproteins and glycolipids, compete with these glycoproteins and glycolipids, and thus prevent the attachment of bacteria and yeasts.
- the invention makes it possible to prevent or limit the process of colonization and infection of pathogenic microorganisms on warm-blooded animals with peel. .
- pentoses and hexoses will advantageously be chosen.
- pentoses mention may be made of D-arabinose.
- hexoses mention may be made of D-fucose, L-fucose, D-galactose, D-glucose, D-mannose and L-rhamnose.
- first or second oligosaccharides capable of entering into the compositions according to the invention
- homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides will advantageously be chosen.
- composition according to the invention further comprises a third mono- or oligosaccharide, said third mono- or oligosaccharide being different from said first and second mono- or oligosaccharides.
- This third mono- or oligosaccharide is advantageously itself able to limit the adhesion of microorganisms on the skin of warm-blooded animals with peel.
- the third mono- or oligosaccharide according to the invention is a monosaccharide, it is advantageously chosen from pentoses and hexoses.
- pentoses mention may be made of D-arabinose.
- hexoses mention may be made of D-fucose, L-fucose, D-galactose, D-glucose, D-mannose and L-rhamnose.
- homogeneous or heterogeneous oligomers consisting of the abovementioned monosaccharides will advantageously be chosen.
- the first, second and / or third mono- or oligosaccharides are advantageously capable of reducing the production of TNF- ⁇ by the keratinocytes of the skin of warm-blooded animals with peel. It will be noted that this action on TNF- ⁇ production has recently been demonstrated, in vitro, on canine keratinocytes ("in vitro assays for canine keratinocyte activation: modulation by fucose, arabinose and rhamnose", C. Ibisch, P. Bourdeau, C. Cadiot and H. Gatto, 17th ESVD-ECVD Congress, Copenhagen 2001). The decrease in TNF- ⁇ production has an immunomodulatory effect and leads to a decrease in cutaneous inflammation.
- the first mono- or oligosaccharide of the composition according to the invention is L-rhamnose or a homogeneous oligomer consisting of L-rhamnose
- the second mono- or oligosaccharide of the composition according to the invention is D-galactose or a homogeneous oligomer consisting of D-galactose
- the third mono- or oligosaccharide of the composition according to the invention is D-mannose or a homogeneous oligomer consisting of D-mannose.
- the composition according to the invention also advantageously comprises an alkylpolyglucoside.
- the alkylpolyglucosides (APG) according to the invention are substances consisting of one or more residues of glucose and an alkyl group, resulting from the condensation of a fatty alcohol with glucose or one of its polymers.
- the alkylpolyglucosides according to the invention are capable of preventing and / or limiting the adhesion of certain microorganisms, such as, in particular, Staphylococcus intermedius, to the skin of warm-blooded animals with fur.
- the presence of such alkylpolyglucosides in the compositions according to the invention therefore makes it possible to broaden the inhibitory action of adhesion to a wider range of microorganisms that are only slightly or not sensitive to the antiadhesive properties of mono- or oligosaccharides.
- the alkylpolyglucoside used in the composition according to the invention is lauryl diglucoside.
- the first, second and / or third mono- or oligosaccharides and / or the alkylpolyglucoside are advantageously contained in micro- or nanoparticulate vectors.
- 5 to 90% of the mono- or oligosaccharides and / or the alkylpolyglucoside are contained in these vectors.
- micro- or nanoparticulate vectors it is possible to use all the vectorization systems allowing a controlled release of the mono- or oligosaccharides according to the invention such as microcapsules, microspheres, macromolecular complexes, nanospheres, nanocapsules, latexes or the vesicles.
- micro or nanoparticulate vectors By way of non-limiting examples of micro or nanoparticulate vectors, mention may be made of the multilammellar vesicles sold by NOVAVAX TM under the name Novasomes TM, spherical multilamellar vesicles with onion structure called Spherulites TM, polyurethane-based microcapsules , polyurea resin, polyamide resin, polyamide-polyurea resin, polycarbonate resin, polysulfonate resin and polysulfonamide resin.
- the Spherulites TM can encapsulate hydrophilic or hydrophobic molecules with encapsulation efficiencies of the order of 90%. The molecules they encapsulate are released gradually. The release of the encapsulated compounds can be regulated kinetically or thermodynamically.
- the micro or nanoparticulate vectors according to the invention have a diameter of between 0.01 ⁇ m and 150 ⁇ m. In the case where these vectors are nanoparticulate vectors, their diameter is preferably between 0.1 ⁇ m and 0.5 ⁇ m and, in the case where these vectors are microparticulate vectors, their diameter is preferably between 1 ⁇ m and 50 ⁇ m. Moreover, the micro or nanoparticulate vectors according to the invention are loaded or uncharged.
- these vectors When these vectors are loaded, they are advantageously cationic.
- these vectors are fixed not only on the skin of animals but also on the hairs of their coat. They provide a regular and controlled release of mono- or oligosaccharides and / or alkylpolyglucoside on the surface of the skin and on the hairs.
- a mechanical action for example cleaning the animal, the benefits of the composition according to the invention are retained. This gradual release effect allows a maintenance in time of the action of mono- or oligosaccharides and / or alkylpolyglucoside on the adhesion of bacteria.
- micro or nanoparticulate vectors according to the invention When the micro or nanoparticulate vectors according to the invention are not charged, they are said to be nonionic. In this case, in addition to the aforementioned prolonged release effect, their presence promotes the diffusion of mono- or oligosaccharides and / or alkylpolyglucoside through the skin. Also, when the mono- or oligosaccharides and / or the alkylpolyglucoside present in the vectors have an inhibitory effect on the activation of keratinocytes and on the secretion of TNF- ⁇ , the effects of reducing cutaneous inflammation are improved.
- the composition according to the invention comprises both cationic micro- or nanoparticulate vectors and nonionic micro- or nanoparticulate vectors.
- the interest lies in the respective contribution of each type of vector to the decrease of the adhesion of the bacteria.
- the mono- or Free oligosaccharides (non-vectorized) and / or free alkylpolyglucoside have a direct and immediate action on the adhesion of bacteria.
- the cationic micro- or nanoparticulate vectors of the composition allow a direct and prolonged action of the mono- or oligosaccharides and / or the alkylpolyglucoside on the adhesion of the bacteria whereas the nonionic micro- or nanoparticulate vectors also exert a anti-irritant effect that reduces inflammation of the skin and reduces the adhesion of bacteria.
- composition according to the invention has both an immunomodulatory effect improved by a better diffusion of mono- or oligosaccharides and / or alkylpolyglucosides encapsulated in nonionic micro- or nanoparticulate vectors through the skin, but also an anti-inflammatory action.
- -adhesive extended by the presence of mono- or oligosaccharides and / or alkylpolyglucosides encapsulated in cationic micro- or nanoparticulate vectors.
- composition according to the invention may furthermore comprise antiseptic agents, chelating agents, keratolytic, kératorégulateurs, antiseborrhéiques agents and cleaning or emollient agents.
- antiseptic agents that can be used in the composition according to the invention, mention may be made of chlorhexidine, hexachlorophene, parachlorometaxylenol, piroctone olamine and triclosan, alone or as a mixture.
- chelating agents that can be used in the composition according to the invention, mention may be made of diethylene triamine pentaacetic and ethylenediaminetetraacetate, taken alone or as a mixture.
- keratolytic agents kératorégulateurs or antiseborrhéigues being able to enter in the composition according to the invention
- cleaning or emollient agents that can be used in the composition according to the invention, mention may be made of linoleic acid, cocoglucoside, decyl glucoside, disodium cocoamphodiacetate, disodium laureth, docusate sodium, sodium stearate and sulfosuccinate, alone or as a mixture.
- topical compositions according to the invention are more particularly intended for the treatment of the skin and the mucous membranes and may be in the form of ointments, creams, milks, ointments, soaked swabs, syndets, solutions , gels, sprays, mousses, suspensions, lotions, shampoos, or washing bases.
- compositions are used as cosmetic or pharmaceutical products for veterinary use. More particularly, they are used for the hygiene of warm-blooded animals, for the control, for the prevention or for the treatment of irritative dermatitis, atopic dermatitis, keratoseborrhoeic syndrome, otitis externa, pyoderma or dermatitis in Malassez ⁇ has warm-blooded animals with peeling.
- the invention thus relates to the use of mono- or oligosaccharides for the preparation of a topical composition for the control aid or for the preparation of a medicament for the treatment of dermatitis irritation, atopic dermatitis, keratoseborrhoeic syndrome, otitis externa, pyoderma, or Malassezia dermatitis in warm-blooded animals with peel, as well as methods for the treatment of these skin conditions in warm-blooded animals with the use of a composition containing mono- or oligosaccharides.
- the choice of mono- or oligosaccharides and / or alkylpolyglucoside present in the composition is determined by the end use of the composition according to the invention.
- the composition according to the invention is a lotion comprising at least two specific monosaccharides, L-fucose and L-rhamnose, these monosaccharides being contained in Spherulites TM type vectors.
- the composition according to the invention is a solution comprising three monosaccharides, L-rhamnose, D-mannose and D-galactose.
- the composition is a shampoo comprising three monosaccharides, as described above, associated with an alkylpolyglucoside.
- Example 1 The present invention will now be illustrated by means of the following Examples 1 and 2: Example 1
- the three strains of Pseudomonas were collected from dogs with infectious otitis. Corneocytes were taken from six different healthy dogs using D-squame TM brand adhesive discs, marketed by CuDerm TM.
- Bacterial suspensions each containing one of the three P1, P2 or P3 strains and PBS (saline phosphate buffer) with or without monosaccharides at two concentrations (0.05% and 0.1%) were prepared. These suspensions were each placed on a layer of corneocytes. These layers were incubated in a humid chamber. After incubation, the corneocytes were washed and stained. Adherent Pseudomonas were then quantified by computer-assisted image analysis.
- PBS saline phosphate buffer
- the percentage of adhesion of the strains in the presence of monosaccharides is then calculated with respect to the percentage of adhesion of the strains without monosaccharides (positive control).
- the percentages of adhesion are compared for the three strains P1 to P3 relative to the positive control (100%).
- the average percentage inhibition for the three strains of Pseudomonas is 25.6% for D-galactose, 19.4% for D-mannose and 30.8% for L-rhamnose. It appears that each of the three monosaccharides limits the adhesion of Pseudomonas to the corneocytes. When the three monosaccharides are used in In combination, surprisingly, an average percent inhibition of 53.4% is observed.
- composition according to the invention There is therefore a conjugation of action when, according to the invention, a plurality of mono- or oligosaccharides, each having anti-adhesive properties are present in the composition. This is at least the case when the composition according to the invention comprises three mono- or oligosaccharides having these properties.
- Example 2 A study comparing the inhibition by alkylpolyglucosides (Plantaren TM 1200) of the adhesion of three different strains of Staphylococcus intermedius, S1, S2, S3, was conducted on canine corneocytes.
- Corneocytes were taken from different healthy dogs, having not undergone topical or systemic treatment in the three weeks prior to collection, using D-Squame TM brand adhesive discs, marketed by CuDerm TM.
- Bacterial suspensions each containing one of the three strains S1, S2 or S3 and PBS were made.
- the percentage of adhesion of the strains in the presence of saccharides is then calculated with respect to percentage of adhesion of strains without saccharides (positive control).
- the percentages of adhesion are compared for the three strs S1 to S3 compared to the positive control (100%).
- the mean percent inhibition for the three strains of Staphylococcus aureus is 47.71% for alkyl polyglucosides.
- alkylpolyglucosides limit the adhesion of Staphylococcus intermedus to the corneocytes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/910,684 US20080200427A1 (en) | 2005-04-04 | 2006-04-04 | Topical Compositions and the Use Thereof |
EP06726173A EP1868618A2 (fr) | 2005-04-04 | 2006-04-04 | Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage |
JP2008504802A JP5107229B2 (ja) | 2005-04-04 | 2006-04-04 | 局所用組成物およびその使用 |
BRPI0612164-0A BRPI0612164A2 (pt) | 2005-04-04 | 2006-04-04 | composição para aplicação tópica e uso de uma composição |
AU2006231248A AU2006231248B2 (en) | 2005-04-04 | 2006-04-04 | Topical compositions comprising several mono- and/or oligosaccharides for treating skin diseases of warm blood hair coated animals. |
US12/881,042 US20100331276A1 (en) | 2005-04-04 | 2010-09-13 | Topical compositions and the use thereof |
US13/103,429 US20110212908A1 (en) | 2005-04-04 | 2011-05-09 | Topical compositions and the use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0503291A FR2883750B1 (fr) | 2005-04-04 | 2005-04-04 | Compositions topiques et leurs utilisations |
FR0503291 | 2005-04-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/881,042 Division US20100331276A1 (en) | 2005-04-04 | 2010-09-13 | Topical compositions and the use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006106220A2 true WO2006106220A2 (fr) | 2006-10-12 |
WO2006106220A3 WO2006106220A3 (fr) | 2007-01-04 |
WO2006106220B1 WO2006106220B1 (fr) | 2007-02-08 |
Family
ID=35431411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2006/000730 WO2006106220A2 (fr) | 2005-04-04 | 2006-04-04 | Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage |
Country Status (7)
Country | Link |
---|---|
US (3) | US20080200427A1 (fr) |
EP (1) | EP1868618A2 (fr) |
JP (1) | JP5107229B2 (fr) |
AU (1) | AU2006231248B2 (fr) |
BR (1) | BRPI0612164A2 (fr) |
FR (1) | FR2883750B1 (fr) |
WO (1) | WO2006106220A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022127997A1 (fr) | 2020-12-16 | 2022-06-23 | MNT Systeme GmbH | UTILISATION DE β-GALACTOOLIGOSACCHARIDES POUR PRODUIRE UN PRODUIT COSMÉTIQUE ET/OU UNE COMPOSITION PHARMACOLOGIQUEMENT ACTIVE |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5737646B2 (ja) * | 2010-03-24 | 2015-06-17 | 森下仁丹株式会社 | 抗アレルギー剤 |
US20170071979A1 (en) * | 2011-05-11 | 2017-03-16 | Veloce Biopharma, Llc | Composition and method for treating otitis |
FR2989274B1 (fr) * | 2012-04-12 | 2016-02-26 | Biochimie Appliquee Soc | Composition cosmetique cutanee et/ou dermatologique destinee a limiter l'adhesion des bacteries pathogenes au niveau de la peau |
US11185557B2 (en) | 2017-07-28 | 2021-11-30 | Isdin, S.A. | Use of rhamnose and derivatives thereof as antifungal agents |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB208690A (en) * | 1922-12-21 | 1924-12-15 | Pharmacia Ab | Pharmaceutical preparation and a method for producing the same |
FR2609397A1 (fr) * | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique |
WO1993014773A1 (fr) * | 1992-01-24 | 1993-08-05 | Soeremark Rune | Composition pharmaceutique et son utilisation |
EP0561489A2 (fr) * | 1992-01-22 | 1993-09-22 | The Mennen Company | Compositions déodorantes contenant des matériaux pour inhiber l'adhérence bactérienne, leur méthode d'utilisation et méthode de détermination de matériaux qui inhibitent l'adhérence bactérienne |
WO1996023479A2 (fr) * | 1995-02-03 | 1996-08-08 | Beiersdorf Ag | Principes actifs anti-adherents |
WO1996039839A1 (fr) * | 1995-06-07 | 1996-12-19 | Henkel Corporation | Complexe iode d'alkyle polyglycosides |
CA2245254A1 (fr) * | 1998-09-02 | 2000-03-02 | Soheyl Mottahedeh | Shampoing a base d'heteroside pour le traitement du psoriasis |
US6214339B1 (en) * | 2000-01-12 | 2001-04-10 | Michael A. Pellico | Di-enzymatic treatment of outer ear infection in dogs and cats |
FR2820038A1 (fr) * | 2001-01-29 | 2002-08-02 | Dermaconcept Jmc | Composition dermatologique a usage veterinaire comprenant une base sphingoide |
WO2002094330A1 (fr) * | 2000-11-28 | 2002-11-28 | Kimberly-Clark Worldwide, Inc. | Non-tisses modifies par des tensio-actifs alkylpolyglycosides |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4518517A (en) * | 1983-03-16 | 1985-05-21 | Colgate-Palmolive Company | Non-antimicrobial deodorant cleansing composition |
US4690825A (en) * | 1985-10-04 | 1987-09-01 | Advanced Polymer Systems, Inc. | Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen |
LU87410A1 (fr) * | 1988-12-20 | 1990-07-10 | Cird | Composition cosmetique ou pharmaceutique contenant des microspheres de polymeres ou de corps gras chargees d'au moins un produit actif |
FR2649888B1 (fr) * | 1989-07-18 | 1994-08-26 | Exsymol Sa | Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques |
US5002759A (en) * | 1989-07-25 | 1991-03-26 | Colgate-Palmolive Company | Oligosaccharide inhibition of Streptococcus pyogenes adhesion |
US6087320A (en) * | 1989-09-14 | 2000-07-11 | Henkel Corp. | Viscosity-adjusted surfactant concentrate compositions |
US6057274A (en) * | 1997-08-22 | 2000-05-02 | Henkel Corporation | Antibacterial composition having enhanced tactile properties |
US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
DE10163246A1 (de) * | 2001-12-21 | 2003-07-10 | Henkel Kgaa | Neue Verwendung von Apfelkernextrakten in kosmetischen oder pharmazeutischen Zusammensetzung |
JP4509517B2 (ja) * | 2002-09-19 | 2010-07-21 | ロート製薬株式会社 | 黄色ブドウ球菌の皮膚付着を阻害し、かつ、表皮ブドウ球菌の皮膚付着を促進させる剤 |
-
2005
- 2005-04-04 FR FR0503291A patent/FR2883750B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-04 EP EP06726173A patent/EP1868618A2/fr not_active Withdrawn
- 2006-04-04 BR BRPI0612164-0A patent/BRPI0612164A2/pt not_active IP Right Cessation
- 2006-04-04 WO PCT/FR2006/000730 patent/WO2006106220A2/fr not_active Application Discontinuation
- 2006-04-04 US US11/910,684 patent/US20080200427A1/en not_active Abandoned
- 2006-04-04 JP JP2008504802A patent/JP5107229B2/ja not_active Expired - Fee Related
- 2006-04-04 AU AU2006231248A patent/AU2006231248B2/en not_active Ceased
-
2010
- 2010-09-13 US US12/881,042 patent/US20100331276A1/en not_active Abandoned
-
2011
- 2011-05-09 US US13/103,429 patent/US20110212908A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB208690A (en) * | 1922-12-21 | 1924-12-15 | Pharmacia Ab | Pharmaceutical preparation and a method for producing the same |
FR2609397A1 (fr) * | 1988-02-23 | 1988-07-15 | Serobiologiques Lab Sa | Utilisation d'une substance ou composition de nature glucidique comme principe actif d'une composition dermatologique et/ou cosmetologique et/ou pharmaceutique et/ou stimulante cellulaire, et composition contenant une telle substance ou composition de nature glucidique |
EP0561489A2 (fr) * | 1992-01-22 | 1993-09-22 | The Mennen Company | Compositions déodorantes contenant des matériaux pour inhiber l'adhérence bactérienne, leur méthode d'utilisation et méthode de détermination de matériaux qui inhibitent l'adhérence bactérienne |
WO1993014773A1 (fr) * | 1992-01-24 | 1993-08-05 | Soeremark Rune | Composition pharmaceutique et son utilisation |
WO1996023479A2 (fr) * | 1995-02-03 | 1996-08-08 | Beiersdorf Ag | Principes actifs anti-adherents |
WO1996039839A1 (fr) * | 1995-06-07 | 1996-12-19 | Henkel Corporation | Complexe iode d'alkyle polyglycosides |
CA2245254A1 (fr) * | 1998-09-02 | 2000-03-02 | Soheyl Mottahedeh | Shampoing a base d'heteroside pour le traitement du psoriasis |
US6214339B1 (en) * | 2000-01-12 | 2001-04-10 | Michael A. Pellico | Di-enzymatic treatment of outer ear infection in dogs and cats |
WO2002094330A1 (fr) * | 2000-11-28 | 2002-11-28 | Kimberly-Clark Worldwide, Inc. | Non-tisses modifies par des tensio-actifs alkylpolyglycosides |
FR2820038A1 (fr) * | 2001-01-29 | 2002-08-02 | Dermaconcept Jmc | Composition dermatologique a usage veterinaire comprenant une base sphingoide |
Non-Patent Citations (2)
Title |
---|
HAUTHAL H G: "ALKYLPOLYGLYCOSIDE FUR EUROPA" SOFW-JOURNAL SEIFEN, OELE, FETTE, WACHSE, VERLAG FUR CHEMISCHE INDUSTRIE, AUGSBURG, DE, vol. 121, no. 9, août 1995 (1995-08), pages 682-684, XP000518443 ISSN: 0942-7694 * |
MEYER W ET AL: "General anti-microbial properties of the integument in fleece producing sheep and goats" SMALL RUMINANT RESEARCH, vol. 41, no. 2, août 2001 (2001-08), pages 181-190, XP002357797 ISSN: 0921-4488 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022127997A1 (fr) | 2020-12-16 | 2022-06-23 | MNT Systeme GmbH | UTILISATION DE β-GALACTOOLIGOSACCHARIDES POUR PRODUIRE UN PRODUIT COSMÉTIQUE ET/OU UNE COMPOSITION PHARMACOLOGIQUEMENT ACTIVE |
DE102020133860A1 (de) | 2020-12-16 | 2022-06-23 | MNT Systeme GmbH | VERWENDUNG VON β-GALAKTOOLIGOSACCHRIDEN FÜR DIE HERSTELLUNG EINER KOSMETISCHEN UND/ODER PHARMAKOLOGISCH WIRKSAMEN ZUSAMMENSETZUNG |
Also Published As
Publication number | Publication date |
---|---|
WO2006106220A3 (fr) | 2007-01-04 |
BRPI0612164A2 (pt) | 2010-10-19 |
EP1868618A2 (fr) | 2007-12-26 |
JP2008534659A (ja) | 2008-08-28 |
FR2883750A1 (fr) | 2006-10-06 |
US20110212908A1 (en) | 2011-09-01 |
JP5107229B2 (ja) | 2012-12-26 |
FR2883750B1 (fr) | 2009-07-31 |
AU2006231248B2 (en) | 2012-08-02 |
WO2006106220B1 (fr) | 2007-02-08 |
AU2006231248A2 (en) | 2006-10-12 |
US20080200427A1 (en) | 2008-08-21 |
AU2006231248A1 (en) | 2006-10-12 |
US20100331276A1 (en) | 2010-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60027455T2 (de) | Oligosaccharidealdonsäure und ihre topische verabreichung | |
EP3311823B1 (fr) | Procédés et compositions pour l' interruption du biofilm utilisant des composés dérivés de chitosane | |
WO1996023479A2 (fr) | Principes actifs anti-adherents | |
EP2911680B1 (fr) | Utilisation d'un extrait de lin provenant de l'hydrolyse des protéines de lin, en tant qu'agent actif antimicrobien | |
EP2739275B1 (fr) | Composition antiseptique | |
WO2006106220A2 (fr) | Compositions topiques comprenant plusieurs mono-et/ou oligosaccharides pour le traitement des maladies cutanees d ' animaux a sang chaud a pelage | |
US9232793B2 (en) | Methods of inhibiting microbial growth using deoxyaldohexoses | |
FR2916634A1 (fr) | Association synergique vis-a-vis de la flore microbienne de l'epiderme humain et applications cosmetiques et pharmaceutiques | |
EP4032542A1 (fr) | Composition antimicrobienne | |
Audus et al. | Chlorhexidine effects on membrane lipid domains of human buccal epithelial cells | |
EP2869827B1 (fr) | Utilisation d'un extrait de myrte en tant qu'agent anti-biofilm vis-a-vis de p. acnes | |
EP1631594A1 (fr) | Nouvel agent stimulant la liberation des beta-endorphines, compositions cosmetiques et/ou dermatologiques en contenant et leurs applications | |
EP0909557B1 (fr) | Utilisation du miel en tant qu'agent diminuant l'adhésion des micro-organismes | |
CA1341359C (fr) | Procede de preparation d'une composition inhibitrice ou destructrice d'au moins un etre vivant unicellulaire renfermant du fluor f- et du lithium li+ | |
EP1283033B1 (fr) | Association d'alkylglycoside et de pyridinecarboxamide | |
FR2989274A1 (fr) | Composition cosmetique cutanee et/ou dermatologique destinee a limiter l'adhesion des bacteries pathogenes au niveau de la peau | |
WO2024121509A1 (fr) | Composition cosmetique /dermatologique comprenant des particules de soie | |
WO1997032479A1 (fr) | Compositions antiseptiques a base de chlorobutanol et de chlorhexidine | |
EP4003269A1 (fr) | Complexe hybride mineral et organique et son utilisation pour le maintien de l'equilibre microbiologique de la peau et/ou d'une composition cosmetique et/ou dermopharmaceutique | |
JP2022134698A (ja) | 皮膚常在菌叢改善剤 | |
Kulshrestha | Nanoparticle induced suppression of microbial biofilm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008504802 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11910684 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006726173 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006231248 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2006231248 Country of ref document: AU Date of ref document: 20060404 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006231248 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006726173 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0612164 Country of ref document: BR Kind code of ref document: A2 |